Keyword: Amgen

News

Novartis and Amgen Partner on Alzheimer’s and Migraine

03.09.2015 - Swiss drugmaker Novartis has announced it will cooperate with US biopharmaceutical group Amgen to develop and sell neuroscience treatments for conditions such as Alzheimer's...

News

FDA Releases Naming Rules for Biosimilars

31.08.2015 - The US Food and Drug Administration has released a proposal for naming biosimilars – lower-cost biotech drugs – almost simultaneously with the market launch of the first such...

News

Amgen Gets Nod for New Cholesterol Drug

31.08.2015 - Amgen has won US Food and Drug Administration (FDA) approval for Repatha, the second medicine in a new class of biologics recently greenlighted by the agency and claimed to reduce...

News

Novartis Can Sell Neupogen Copy in US in September

24.07.2015 - A US federal appeals court has ruled that Swiss drugmaker Novartis can begin selling Zarxio, its lower-cost generic version of an Amgen drug, on the US market starting in September...

News

Celgene Offers $7.2 Billion for Receptos

17.07.2015 - US biotech firm Celgene has agreed to pay $7.2 billion, or $232 per share, to acquire compatriot Receptos, a biotech company that makes a potential blockbuster drug to treat...

News

AstraZeneca Weighs Continuation of Psoriasis Drug

11.06.2015 - AstraZeneca is mulling whether to independently pursue the developmental psoriasis drug brodalumab after its partner Amgen’s withdrawal from the project in May, Pascal Soriot...

News

FDA Approves the First-Ever US Biosimilar

16.03.2015 - The US Food & Drug Administration has approved the country's first biosimilar product, a move observers say will open the door for lower cost, generic-like biological drugs. The...

News

Adaptimmune Strengthens Management Team with Key Executive Hires

05.03.2015 - Adaptimmune announced the appointments of Dr. Rafael Amado as Chief Medical Officer and Adrian (Ad) Rawcliffe as Chief Financial Officer, with effect of March 16, 2015. Dr. Amado...